Related Experiment Video
Updated: Feb 24, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review
Asmae Sikkal1, Salma Ouahmane1, Hicham El Otmani1,2
1Department of Neurology and Clinical Neurophysiological Explorations, Ibn Rochd University Hospital of Casablanca, Casablanca, MAR.
Rituximab can cause rare immune reactions like serum sickness in multiple sclerosis patients. This case highlights the importance of monitoring for delayed reactions and considering alternative anti-CD20 therapies.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Rituximab, an anti-CD20 monoclonal antibody, is increasingly used for multiple sclerosis (MS).
- Rarely, rituximab can trigger delayed immune-mediated reactions, including rituximab-induced serum sickness.
More Related Videos
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
10:27Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Hypersensitivity Reactions: Immune-Complex Reactions
Rheumatic Heart Disease I: Introduction